US 12,246,166 B2
Integrated insulin delivery system with continuous glucose sensor
John Michael Dobbles, San Clemente, CA (US); Apurv Ullas Kamath, San Diego, CA (US); Aarthi Mahalingam, San Diego, CA (US); and James H. Brauker, Addison, MI (US)
Assigned to Dexcom, Inc., San Diego, CA (US)
Filed by DexCom, Inc., San Diego, CA (US)
Filed on Jul. 26, 2024, as Appl. No. 18/785,610.
Application 18/785,610 is a continuation of application No. 17/074,490, filed on Oct. 19, 2020.
Application 17/074,490 is a continuation of application No. 16/867,476, filed on May 5, 2020, granted, now 10,835,672, issued on Nov. 17, 2020.
Application 16/867,476 is a continuation of application No. 15/792,038, filed on Oct. 24, 2017, granted, now 10,653,835, issued on May 19, 2020.
Application 15/792,038 is a continuation of application No. 15/362,571, filed on Nov. 28, 2016, granted, now 9,827,372, issued on Nov. 28, 2017.
Application 15/362,571 is a continuation of application No. 14/063,811, filed on Oct. 25, 2013, granted, now 9,597,453, issued on Mar. 21, 2017.
Application 14/063,811 is a continuation of application No. 13/885,604, granted, now 9,452,258, issued on Sep. 27, 2016, previously published as PCT/US2007/080848, filed on Oct. 9, 2007.
Prior Publication US 2024/0382679 A1, Nov. 21, 2024
Int. Cl. A61M 5/172 (2006.01); A61B 5/145 (2006.01); A61M 5/142 (2006.01); A61M 5/20 (2006.01); A61M 11/00 (2006.01); A61M 15/00 (2006.01); A61M 35/00 (2006.01); G16H 20/17 (2018.01); G16H 40/63 (2018.01); A61B 5/00 (2006.01); A61M 5/00 (2006.01); A61M 5/178 (2006.01); A61M 5/30 (2006.01)
CPC A61M 5/1723 (2013.01) [A61B 5/14532 (2013.01); A61B 5/14546 (2013.01); A61M 5/14244 (2013.01); A61M 5/14276 (2013.01); A61M 5/20 (2013.01); A61M 11/00 (2013.01); A61M 15/0065 (2013.01); A61M 15/0068 (2014.02); A61M 15/008 (2014.02); A61M 15/0083 (2014.02); A61M 35/00 (2013.01); G16H 20/17 (2018.01); G16H 40/63 (2018.01); A61B 5/0031 (2013.01); A61M 5/003 (2013.01); A61M 2005/14296 (2013.01); A61M 5/178 (2013.01); A61M 5/30 (2013.01); A61M 15/00 (2013.01); A61M 2205/3569 (2013.01); A61M 2205/50 (2013.01); A61M 2205/502 (2013.01); A61M 2205/52 (2013.01); A61M 2205/581 (2013.01); A61M 2205/582 (2013.01); A61M 2205/587 (2013.01); A61M 2205/8206 (2013.01); A61M 2230/201 (2013.01)] 30 Claims
OG exemplary drawing
 
1. A method for determining insulin therapy for a patient, the method comprising:
receiving, by a user interface of a receiver device that comprises the user interface, a display, and one or more processor modules, input from a user, wherein the input from the user programs a selectable glucose target;
receiving, by the one or more processor modules of the receiver device, at least a first glucose concentration, wherein the first glucose concentration is measured in a bodily fluid of the patient by a continuous glucose sensor;
generating a predicted glucose concentration, wherein the predicted glucose concentration comprises a prediction of a second glucose concentration at a time subsequent to the first glucose concentration, wherein the prediction is generated based at least in part on an algorithm;
deriving, by the one or more processor modules of the receiver device, internal data,
wherein the internal data comprises one or more of:
an insulin sensitivity of the patient,
a change in insulin sensitivity of the patient,
a metabolic response of the patient to insulin therapy,
an amount of insulin delivered to the patient,
a time of insulin delivery to the patient, and/or
an insulin on board of the patient;
calculating, by the one or more processor modules of the receiver device, an insulin therapy instruction by evaluating at least the first glucose concentration, the internal data, and the selectable glucose target,
wherein the insulin therapy instruction is calculated at least in part by evaluating a relationship between the predicted glucose concentration and the selectable glucose target,
wherein a subsequent glucose concentration measured in a bodily fluid of the patient by the continuous glucose sensor following administration of insulin in accordance with the insulin therapy instruction has a desired relationship to the selectable glucose target,
wherein the desired relationship comprises one or more of:
 the subsequent glucose concentration measured in a bodily fluid of the patient by the continuous glucose sensor is at or within the selectable glucose target, and/or
 a euglycemic relationship between the subsequent glucose concentration measured in a bodily fluid of the patient by the continuous glucose sensor and the selectable glucose target; and
transmitting the insulin therapy instruction for use by an insulin delivery device.